Arterial thrombosis for the interventional cardiologist: From adhesion molecules and coagulation factors to clinical therapeutics

Catheterization and Cardiovascular Interventions

Volumn 60, Issue 2, 2003, Pages 236-246

  Conde, Ian D ^a   Kleiman, Neal S ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MS F 1090 ^*  (United States)

Author keywords

Antiplatelet; Antithrombin; Coagulation; Platelet; Therapy; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; CELL ADHESION MOLECULE; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN COFACTOR II; TICLOPIDINE; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOPLASTY; ARTERY THROMBOSIS; BLOOD CLOTTING; CARDIOLOGY; CELL INTERACTION; HUMAN; INFLAMMATION; LEUKOCYTE; RESTENOSIS; REVIEW; SUBENDOTHELIUM; THROMBOCYTE; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

ARTERIAL OCCLUSIVE DISEASES; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CARDIOLOGY; CELL ADHESION MOLECULES; CORONARY DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; INTERVENTION STUDIES; PLATELET ADHESIVENESS; PLATELET AGGREGATION;

EID: 0141790837     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10635     Document Type: Review

References (91)

1. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biologic amplifier. Nature 1964;202: 498-499.
2. Friedman M, van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966;46:19-44.
3. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001;86:178-188.
4. Siegelman M. More than the sum of the parts: cooperation between leukocyte adhesion receptors during extravasation. J Clin Invest 2001;107:159-160.
5. Sadler JE, Matsushita T, Dong Z, Tuley EA, Westfield LA. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost 1995;74:161-166.
6. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998;91:4397-4418.
7. Watson SP, Gibbins J. Collagen receptor signalling in platelets: extending the role of the ITAM. Immunol Today 1998;19:260-264.
8. Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997; 29:91-105.
9. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets: evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990;265:17420-17423.
10. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-874.
11. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-562.
12. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000;192:193-204.
13. Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest 1986;78:130-137.
14. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995;92:7450-7454.
15. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88:3259-3287.
16. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996;88:146-157.
17. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion: signal integration and NF-kappaB translocation. J Clin Invest 1995;95:2297-2303.
18. Koike J, Nagata K, Kudo S, Tsuji T, Irimura T. Density-dependent induction of TNF-alpha release from human monocytes by immobilized P-selectin. FEBS Lett 2000;477:84-88.
19. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996;97:1525-1534.
20. Tsuji T, Nagata K, Koike J, Todoroki N, Irimura T. Induction of superoxide anion production from monocytes an neutrophils by activated platelets through the P-selectin-sialyl Lewis X interaction. J Leukoc Biol 1994;56:583-587.
21. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994;91:8767-8771.
22. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000;20:2322-2328.
23. Neumann FJ, Ott I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996;27:819-824.
24. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol 1996;28:345-353.
25. Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996;28:1127-1133.
26. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000;86:1057-1062.
27. Osada M, Takeda S, Ogawa R, Komori S, Tamura K. T lymphocyte activation and restenosis after percutaneous transluminal coronary angioplasty. J Interferon Cytokine Res 2001;21:219-221.
28. Serrano CV Jr, Ramires JA, Venturinelli M, Arie S, D'Amico E, Zweier JL, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997;29:1276-1283.
29. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001;21:327-334.
30. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000;84:83-87.
31. Bienvenu JG, Tanguay JF, Theoret JF, Kumar A, Schaub RG, Merhi Y. Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation 2001;103: 11281134.
32. Tanguay JF, GP, TJ. Recombinant soluble P-selectin glycoprotein Ligand-1 (rPSGL-Ig) inhibits in-stent restenosis in porcine coronary arteries after double injury. Proceedings of the 18th Congress of the International Society on Thrombosis and Haemostasis; 2001.
33. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol 2001;38:577-582.
34. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998;95:10134-10139.
35. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907-914.
36. Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation: relationship to the binding of fibrinogen and platelet aggregation. Blood 1987;70: 475-483.
37. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-33.
38. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 1983; 29:249-255.
39. Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest 1997;100(Suppl 11):S91-S95.
40. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-1294.
41. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993;82:505-512.
42. Second International Study of Infarct Survival collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
43. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I, prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
44. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
45. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial-ASA and Carotid Endarterectomy (ACE) trial collaborators. Lancet 1999;353:2179-2184.
46. Cattaneo M. Hereditary defect of the platelet ADP receptor(s). Platelets 1998;8:161-164.
47. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-232.
48. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
49. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis study investigators. N Engl J Med 1998;339:1665-1671.
50. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
51. PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
52. PRISM study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
53. PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
54. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial-a randomized controlled trial. JAMA 2001;285:2468-2473.
55. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: evaluation of platelet IIb/IIIa inhibition in stenting investigators. N Engl J Med 1999;341:319-327.
56. Davie EW, Ratnoff OD. Waterfall sequence of intrinsic blood clotting. Science 1964;145:1310-1312.
57. Loscalzo J, Schafer AI. Thrombosis and hemorrhage, 2nd ed. Baltimore: Williams and Wilkins; 1998.
58. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-399.
59. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease, Blood Coagul Fibrinolysis 1995;6(Suppl 1):S26-S31.
60. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-2800.
61. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000;97:13835-13840.
62. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994;153:3245-3255.
63. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315.
64. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000;96: 170-175.
65. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002;100:2787-2792.
66. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598.
67. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359:848-851.
68. Kumar A, Villani MP, Patel UK, Keith JC Jr, Schaub RG. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999;99: 1363-1369.
69. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990;29:1118-1128.
70. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74: 5260-5264.
71. Tracy PB. Regulation of thrombin generation at cell surfaces. Semin Thromb Hemost 1999;14:227-233.
72. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979;254:10952-10962.
73. Gailani D, Broze GJ Jr. Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993;19:396-404.
74. Hoffman M, Monroe DM, III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
75. Fay PJ. Subunit structure of thrombin-activated human factor VIIIa. Biochim Biophys Acta 1988;952:181-190.
76. Nesheim ME, Mann KG. Thrombin-catalyzed activation of single chain bovine factor V. J Biol Chem 1979;254:1326-1334.
77. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997;99:1351-1360.
78. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698.
79. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002;109:213-219.
80. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983;258:6713-6716.
81. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 1987; 262:169-175.
82. Bertina RM, van dL I, Engesser L, Muller HP, Brommer EJ. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987;57:196-200.
83. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000;30(Suppl 2):48-56.
84. Hansen JB, Olsen R, Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood 1997;90:3568-3578.
85. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-813.
86. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1997;47:389-400.
87. Anderson S, Cohen AT, Melissari E, Scully MS, Kakkar VV. Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA. Thromb Haemost 1995;73:328-329.
88. Bendz B, Hansen JB, Andersen TO, Ostergaard P, Sandset PM. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 1999;107:756-762.
89. Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation. Curr Opin Hematol 2001;8:263-269.
90. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995;270:20794-20800.
91. Colucci M, Stramaglia AM, Mascolo E, Napoleone E, Lorenzet R, Semeraro N. Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C. Br J Haematol 2001;112:519-526.